New Signalling Targets Investigated in Phase I Trial

Clinical Pharmacology and Trials Team

Section: Section of Cancer Therapeutics (including the Cancer Research UK Centre for Cancer Therapeutics)

mTOR

Vascular Endothelial Growth Factor Receptors (VEGFR)

RAF

Histone deacetylase (HDAC)

Cell surface death receptors

HER-2

Kinesins

Reovirus (targets RAS-activated cells)

Cyclin dependent kinases

Poly-ADP ribose polymeras

Epidermal Growth Factor Receptor (EGFR)

Heat Shock Protein 90 (HSP-90)

CYP17 (inhibitor of androgen biosynthesis)

Insulin-like Growth Factor 1 Receptor (IGF1-R)

Aurora kinase

Survivin

MET

SRC

Polo-like kinase (PLK)

Phosphatidyl inositol-3 kinase (PI3 kinase)